GlassScriptPhysician profile
Colden Thomas Odell
NPI 1396216826
$2,853.32
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $69.05 · 2023: $1,444 · 2024: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,759 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,759.27 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.90 | 2023-2024 | |
| Lilly USA, LLC | $404.54 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $265.28 | 2023-2024 | Repatha, Evenity, Prolia |
| Glaxosmithkline, LLC. | $169.84 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $157.91 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.10 | 2023-2024 | Jardiance |
| Pfizer INC. | $124.29 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $112.64 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.56 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.12 | 2023-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $95.35 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $75.72 | 2023-2024 | Airsupra, Farxiga |
| Idorsia Pharmaceuticals US INC | $66.35 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $65.98 | 2024 | Rexulti |
| Corium, LLC | $56.33 | 2023 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.12 | 2022-2024 | Caplyta |
| Heartflow, INC. | $48.84 | 2023-2024 | Ffrct |
| Boston Scientific Corporation | $46.22 | 2024 | Watchman Flx |
| Astellas Pharma US INC | $41.98 | 2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $37.13 | 2023-2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $34.59 | 2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $34.25 | 2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $29.39 | 2023-2024 | Verquvo, Belsomra |
| Edwards Lifesciences Corporation | $28.68 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Dexcom, INC. | $24.18 | 2024 | Dexcom G6 Transmitter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.84 | 2023 | Lifevest |
| Forte Bio-Pharma LLC | $7.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colden Odell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.